Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)


Friday 13 May, 2022

Oxford BioDynamics

PDMR Dealing / Grant of Share Options

RNS Number : 5030L
Oxford BioDynamics PLC
13 May 2022

13 May 2022 


Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")


PDMR Dealing / Grant of Share Options


Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces that it has today granted a total of 571,757 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 501,757 options to Chief Executive Officer, Dr Jon Burrows. The options were granted under the Company's 2016 Employee Share Option Plan with an exercise price of 17.25p per share.


One-third of the options granted to Dr Burrows will vest and become exercisable on each of 23 March 2023, 23 March 2024 and 23 March 2025. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.


Following this grant, Dr Jon Burrows, holds options over Ordinary Shares and is interested in Ordinary Shares as follows:


Total number of options over Ordinary Shares

Ordinary Shares held


% of current issued share capital

Jon Burrows





The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.



Details of the person discharging managerial responsibilities/person closely associated



Jon Burrows


Reason for the notification





Initial notification/ Amendment 

Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Oxford BioDynamics Plc 





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each


ISIN:  GB00BD5H8572


Nature of the transaction

Grant of share options


Price(s) and volume(s)

501,757 ordinary shares at an exercise price of 17.25 pence per share




Aggregated information

- Aggregated volume

- Price






Date of the transaction

13 May 2022



Place of the transaction

Outside a trading venue








For further details please contact:


Oxford BioDynamics Plc

Jon Burrows, CEO

Paul Stockdale, CFO


Tel: +44 (0)1865 518910

Shore Capital - Nominated Adviser and Broker

Advisory: Stephane Auton / John More

Broking: Fiona Conroy


Tel: +44 (0)20 7408 4090

Instinctif Partners

Melanie Toyne-Sewell / Jonjo Cordey

Tel: +44 (0)20 7457 2020

[email protected]




Notes for Editors


About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is  EpiSwitch® CiRT  (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test,  EpiSwitch ®   CST  (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery,  EpiSwitch® Explorer Array Kit

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, , or follow on  Twitter  or  LinkedIn .

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t